Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2023 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 17, 2023-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Monday, July 31, 2023 to discuss its
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 3, 2023-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”)
View HTML
Toggle Summary ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress
Interim Analysis from Phase 2 Trial Demonstrates Compelling Anti-Tumor Activity in Patients with Frontline and Relapsed/Refractory BPDCN; No New Safety Signals Identified Enrollment Continues in Frontline CADENZA Cohort; Top-Line Pivotal Data Expected in 2024 WALTHAM, Mass. --(BUSINESS WIRE)--Jun.
View HTML
Toggle Summary ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer
Results from MIRASOL Also Show ELAHERE is the First Treatment to Demonstrate an Overall Survival Benefit in a Phase 3 Trial in Platinum-Resistant Ovarian Cancer Compared to Chemotherapy Clinically Meaningful Improvements in Progression Free Survival and Overall Survival Observed with ELAHERE
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 1, 2023-- June 1, 2023 – ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)--May 24, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, and Anna Berkenblit , Chief Medical Officer, will participate in a
View HTML
Toggle Summary ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
WALTHAM, Mass. --(BUSINESS WIRE)--May 9, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 29,900,000 shares of its common
View HTML
Toggle Summary ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting
Data from Confirmatory Trial to be Highlighted in Oral Presentation on Sunday, June 4 WALTHAM, Mass. --(BUSINESS WIRE)--May 9, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that results from the
View HTML
Toggle Summary ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)--May 4, 2023-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an underwritten public offering of 26,000,000 shares of its common stock at a price of $12.50
View HTML
Toggle Summary ImmunoGen Announces Proposed Public Offering of Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)--May 3, 2023-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it intends to offer and sell, subject to market and other conditions, $200 million of shares of its
View HTML